Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $540
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $500 to $540.
February 06, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal has reaffirmed an Overweight rating on Vertex Pharmaceuticals and raised the price target from $500 to $540.
The increase in the price target by a reputable analyst such as Mohit Bansal suggests a strong confidence in Vertex Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100